市場調查報告書
商品編碼
995629

骨髓增生性腫瘤治療藥物市場市場規模,份額,前景,機會分析:2020-2027

Myeloproliferative Neoplasm Drugs Market, by Drug Class, by Indication (Ph+ Chronic myelogenous leukemia, Ph- Myeloproliferative Neoplasms, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日期: | 出版商: Coherent Market Insights | 英文 222 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

骨髓增生性腫瘤(MPN)是一種罕見的血液癌,可導致個體骨髓中過多的紅細胞,白細胞或血小板生成。領先的公司正在關注諸如併購等戰略,並有望推動全球骨髓增生性腫瘤藥物市場的增長。

本報告對全球骨髓增生性腫瘤治療藥物市場進行了研究和分析,並系統地提供了市場概況,市場規模和預測,按細分市場的分析,按地區進行的市場分析,競爭情況等。

目錄

第1章調查目標和前提條件

第2章市場範圍

第3章市場動態/法規/趨勢分析

  • 促進因素
  • 抑製器
  • 市場機會
  • 影響分析
  • 主要發展
  • 產品發佈/批准
  • 併購,聯盟
  • 管道分析
  • 監管情況
  • PEST分析
  • 流行病學
  • 市場份額分析

第4章,全球骨髓增生性腫瘤治療市場,COVID-19大流行的影響

  • 供方和需方分析
  • COVID-19對整個醫療保健行業的影響
  • COVID-19對臨床試驗和藥物開發的影響
  • COVID-19對癌症治療的作用

第5章:全球骨髓增生性腫瘤治療市場:按藥物分類

  • 簡介
  • 市場份額分析
  • 同比增長率分析
  • 脫甲基劑
  • 酪氨酸激□抑製劑
  • 多激□抑製劑
  • JAK2抑製劑
  • 其他

第6章:全球骨髓增生性腫瘤治療市場:適應症

  • 簡介
  • 市場份額分析
  • 同比增長率分析
  • 細分趨勢
    • Ph +慢性粒細胞性白血病(CML)
    • 骨髓增生性腫瘤(MPN)
    • 骨髓纖維化(MF)
    • 真性紅細胞增多症(PV)
    • 原發性血小板增多症(ET)

第7章:全球骨髓增生性腫瘤治療市場:通過分銷渠道

  • 簡介
  • 市場份額分析
  • 同比增長率分析
  • 細分趨勢
    • 醫院藥房
    • 零售藥房
    • 在線藥房

第8章全球骨髓增生性腫瘤治療市場:按地區

  • 簡介
  • 市場份額分析:按國家
  • 同比增長率分析:按國家
  • 北美
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章競爭情況

  • 公司簡介
  • Novartis International AG
  • 臨床試驗階段產品組合
  • PharmaEssentia Corporation
  • 臨床試驗階段產品組合
  • Bristol - Myers Squibb
  • 臨床試驗階段產品組合
  • Pfizer, Inc.
  • 臨床試驗階段產品組合
  • Takeda Pharmaceutical Company Limited
  • 臨床試驗階段產品組合
  • Incyte
  • 臨床試驗階段產品組合
  • Johnson & Johnson
  • 臨床試驗階段產品組合
  • Teva Pharmaceutical Industries Ltd.
  • 臨床試驗階段產品組合
  • F. Hoffmann-La Roche AG
  • 臨床試驗階段產品組合
  • Gamida Cell
  • 臨床試驗階段產品組合
  • Sierra Oncology, Inc.
  • 臨床試驗階段產品組合
  • CTI BioPharma Corp.
  • 臨床試驗階段產品組合
  • Imago BioSciences
  • 臨床試驗階段產品組合
  • AbbVie Inc.
  • 臨床試驗階段產品組合
  • Constellation Pharmaceuticals
  • 臨床試驗階段產品組合
目錄

Title:
Myeloproliferative Neoplasm Drugs Market, by Drug Class (Demethylation Agents, Tyrosine kinase Inhibitor, Multikinase Inhibitors, JAK2 Inhibitor, and Others), by Indication (Ph+ Chronic myelogenous leukemia (CML), Ph- Myeloproliferative Neoplasms (MPNs) (Myelofibrosis (MF), Polycythemia Vera (PV), Essential Thrombocythemia (ET)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Myeloproliferative neoplasms (MPNs) are a type of rare blood cancers, which leads to production of excess red blood cells, white blood cells, or platelets in the bone marrow of individuals. Myelo refers to bone marrow and spinal cord of the individual and proliferative describes the rapid growth of blood cells, whereas neoplasm describes the abnormal and uncontrolled growth of cells in patients. The overproduction of blood cells is often associated with a somatic mutation, for example, the over production of JAK2 (Janus kinase 2) leads to chronic myeloproliferative disorders. The various drug classes indicated for the treatment of myeloproliferative neoplasm are demethylation agents, tyrosine kinase inhibitor, multikinase inhibitors, JAK2 inhibitor, and others.

Market Dynamics

Key companies are focusing on strategies such as mergers and acquisitions, which is expected to drive the global myeloproliferative neoplasm drugs market growth. For instance, in January 2019, Takeda Pharmaceutical Company Limited acquired Shire Inc (a biopharmaceutical company in U.K.),to expand its geographical presence in the market and enhance its product portfolio through research and development activities.

Moreover, key players are focusing on product launches and product approvals to strengthen their presence in the global myeloproliferative neoplasm drugs market. For instance, in November 2018, Pfizer Inc. received the U.S. Food and Drug Administration approval for Daurismo for use in adults with acute myeloid leukemia (AML) in 75 years or older patients.

Furthermore, in December 2017, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for a supplemental New Drug Application (sNDA) to expand the indication of BOSULIF (bosutinib) to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).

Key features of the study:

  • This report provides in-depth analysis of the global myeloproliferative neoplasm drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020-2027)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
  • It profiles leading players in the global myeloproliferative neoplasm drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
  • The global myeloproliferative neoplasm drugs market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global myeloproliferative neoplasm drugs market

Detailed Segmentation:

  • Global Myeloproliferative Neoplasm Drugs Market, By Drug Class:
    • Demethylation Agents
    • Tyrosine kinase Inhibitor
    • Multikinase Inhibitors
    • JAK2 Inhibitor
    • Others
  • Global Myeloproliferative Neoplasm Drugs Market, By Indication:
    • Ph+ Chronic myelogenous leukemia (CML)
    • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
  • Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Myeloproliferative Neoplasm Drugs Market, By Region:
    • North America
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Novartis International AG.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bristol - Myers Squibb
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Incyte
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG
    • Gamida Cell
    • Sierra Oncology, Inc.
    • CTI BioPharma Corp.
    • Imago BioSciences
    • AbbVie Inc.
    • Constellation Pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

  • Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations
  • Market Purview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)
  • Market Dynamics, Regulations, and Trends Analysis
  • Drivers
  • Restraints
  • Opportunities
  • Impact Analysis
  • Key Developments
  • Product Launch/ Approvals
  • Mergers, Acquisition & Collaboration
  • Pipeline Analysis
  • Regulatory Scenario
  • PEST Analysis
  • Epidemiology
  • Market Share Analysis
  • Global Myeloproliferative Neoplasm Drugs Market, Impact of COVID-19 Pandemic
  • Supply Side and Demand Side Analysis
  • COVID-19 Impact on Overall Healthcare Sector
  • COVID-19 Impact on Clinical Trials and Drug Development
  • COVID-19 Impact on Cancer Treatment
  • Global Myeloproliferative Neoplasm Drugs Market, By Drug Class, 2016-2027 (US$ Mn)
  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
    • Segment Trends
  • Demethylation Agents
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • Tyrosine kinase Inhibitor
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • Multikinase Inhibitors
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • JAK2 Inhibitor
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • Others
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • Global Myeloproliferative Neoplasm Drugs Market, By Indication, 2016 - 2027, (US$ Mn)
  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017- 2027
  • Segment Trends
    • Ph+ Chronic myelogenous leukemia (CML)
  • Introduction
  • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
    • Ph- Myeloproliferative Neoplasms (MPNs)
  • Introduction
  • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
    • Myelofibrosis (MF)
    • Polycythemia Vera (PV)
    • Essential thrombocythemia (ET)
  • Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel, 2016-2027 (US$ Mn)
  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017- 2027
  • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
  • Global Myeloproliferative Neoplasm Drugs Market, By Region, 2016-2027 (US$ Mn)
  • Introduction
  • Market Share Analysis, By Country, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, For Countries, 2017-2027
  • North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2020-2027 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa
  • Competitive Landscape
  • Company Profiles
  • Novartis International AG
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • PharmaEssentia Corporation
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Bristol - Myers Squibb
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Pfizer, Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Takeda Pharmaceutical Company Limited
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Incyte
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Johnson & Johnson
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • F. Hoffmann-La Roche AG
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Gamida Cell
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Sierra Oncology, Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • CTI BioPharma Corp.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Imago BioSciences
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • AbbVie Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Constellation Pharmaceuticals
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies